Table 2.

Changes in liver fibrosis markers after DAA treatment.

	Baseline	48 W	96 W	144 W	p-value†
Liver stiffness, kPa	19.37 ± 12.86	13.88 ± 9.13	11.70 ± 8.23	10.09 ± 6.23	< 0.001
FIB-4	6.29 ± 4.67	3.25 ± 2.14	2.87 ± 1.59	2.89 ± 1.70	< 0.001
APRI	1.36 ± 0.86	0.66 ± 0.62	0.50 ± 0.29	0.43 ± 0.21	< 0.001

^†K-paired sample Friedman tests were used as normality tests were not satisfied.

DAA, direct antiviral agent; FIB-4, fibrosis-4; APRI, Aspartate transaminase to platelet ratio index; W, week.